Xenon Pharmaceuticals (XENE) Upgraded at ValuEngine

Xenon Pharmaceuticals (NASDAQ:XENE) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.

Separately, Zacks Investment Research raised Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, October 5th.

Xenon Pharmaceuticals (NASDAQ:XENE) opened at $3.25 on Friday. Xenon Pharmaceuticals has a 52-week low of $2.10 and a 52-week high of $9.95. The company has a market capitalization of $59.41, a PE ratio of -2.04 and a beta of 1.46.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.35). Xenon Pharmaceuticals had a negative return on equity of 53.33% and a negative net margin of 4,268.70%. analysts forecast that Xenon Pharmaceuticals will post -1.49 EPS for the current fiscal year.

In other news, Director Mohammad Azab bought 15,000 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, November 15th. The shares were purchased at an average cost of $2.22 per share, with a total value of $33,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.40% of the company’s stock.

An institutional investor recently raised its position in Xenon Pharmaceuticals stock. Scotia Capital Inc. lifted its position in Xenon Pharmaceuticals Inc (NASDAQ:XENE) by 36.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,629 shares of the biopharmaceutical company’s stock after purchasing an additional 9,426 shares during the quarter. Scotia Capital Inc. owned about 0.20% of Xenon Pharmaceuticals worth $112,000 at the end of the most recent reporting period. Institutional investors own 54.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Xenon Pharmaceuticals (XENE) Upgraded at ValuEngine” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/04/xenon-pharmaceuticals-xene-upgraded-at-valuengine.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply